Some newer biologic medications for moderate to severe psoriasis may be less likely to cause side effects compared to adalimumab (sold as Humira), according to a large study from Spain.
Biologics are therapies that target specific parts of the immune system that drive inflammation and cause psoriasis symptoms. Like many medications, biologics can cause side effects, including infections and injection site reactions.
For this study, researchers compared the safety of different biologics and other systemic medications for psoriasis, using data collected from dermatology practices.
Researchers analyzed data from 4,212 people with psoriasis who’d had treatment between 2008 and 2023. The study found that several biologics were linked to a significantly lower rate of adverse events (side effects) than adalimumab. Compared with adalimumab, the risk of adverse events was lower with the following treatments:
Some treatments, such as dimethyl fumarate and infliximab, had higher rates of side effects than adalimumab.
Researchers noted the following side effects:
Although all biologics can cause side effects — most often infections — their safety profiles can differ. The study didn’t directly examine the reasons for these differences. However, some research suggests that targeting different immune pathways may contribute to why certain drugs cause fewer side effects.
Each person’s experience with a biologic can vary — what works well for one may not be the best fit for another. If you’re taking a biologic for psoriasis, it’s important to:
Learn more about the pros and cons of biologics for treating psoriasis.
On MyPsoriasisTeam, people share their experiences with psoriasis, get advice, and find support from others who understand.
Have you noticed different side effects with the psoriasis treatments you’ve tried? Let others know in the comments below.
Get updates directly to your inbox.
Sign up for free!
Become a member to get even more
We'd love to hear from you! Please share your name and email to post and read comments.
You'll also get the latest articles directly to your inbox.